fbpx

DHSC supply alerts for Delmosart tablets, Salofalk suppositories, and Jext auto-injectors – Latest Pharmacy News | Business | Magazine

DHSC supply alerts for Delmosart tablets, Salofalk suppositories, and Jext auto-injectors – Latest Pharmacy News | Business | Magazine

The Department of Health and Social Care (DHSC) on Friday issued multiple medicine supply notifications regarding the shortages of Delmosart tablets, Salofalk suppositories, and Jext adrenaline auto-injectors.

Delmosart (methylphenidate) 18mg prolonged-release tablets are out of stock until mid-November 2019 while all other strengths remain available, along with all other brands.

For patients without sufficient supplies, prescribers are asked to switch to an alternative brand.

Salofalk (mesalazine) 500mg suppositories are out of stock and 1g suppositories will be out of stock from late November. Both stocks are expected to be back by December mid-week.

In case of insufficient supplies, prescribers are asked to switch to Pentasa 1g suppositories which remain available during this period.

As the UK licensed Jext 300 microgram devices are currently unavailable, the Medicines and Healthcare Products Regulatory Agency (MHRA) allowed manufacturer ALK-Abello Ltd to import a quantity of the product from Austria.

Although not licensed in the UK, the devices in Austrian packaging are equivalent to the UK licensed products.

Pharmacies can place orders for the unlicensed Jext 300 microgram via Alliance Healthcare using the PIP code: 801-6941.

Health care professionals are asked to contact [email protected] in case of any queries regarding the above supply notifications.

Original Source



Amazon’s 30-Day FREE Trials






x